CO2020001983A2 - Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anticd39 - Google Patents
Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anticd39Info
- Publication number
- CO2020001983A2 CO2020001983A2 CONC2020/0001983A CO2020001983A CO2020001983A2 CO 2020001983 A2 CO2020001983 A2 CO 2020001983A2 CO 2020001983 A CO2020001983 A CO 2020001983A CO 2020001983 A2 CO2020001983 A2 CO 2020001983A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- methods
- compositions
- homologues
- isoforms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539527P | 2017-07-31 | 2017-07-31 | |
| PCT/US2018/044449 WO2019027935A1 (en) | 2017-07-31 | 2018-07-30 | ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020001983A2 true CO2020001983A2 (es) | 2020-04-01 |
Family
ID=65233024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0001983A CO2020001983A2 (es) | 2017-07-31 | 2020-02-25 | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anticd39 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US20190062448A1 (enExample) |
| EP (1) | EP3661966A4 (enExample) |
| JP (4) | JP7113071B2 (enExample) |
| KR (2) | KR102718932B1 (enExample) |
| CN (2) | CN111448211B (enExample) |
| AR (1) | AR112639A1 (enExample) |
| AU (1) | AU2018312251B2 (enExample) |
| BR (1) | BR112020002012A8 (enExample) |
| CA (1) | CA3071540A1 (enExample) |
| CL (1) | CL2020000281A1 (enExample) |
| CO (1) | CO2020001983A2 (enExample) |
| CR (1) | CR20200101A (enExample) |
| DO (1) | DOP2020000021A (enExample) |
| IL (2) | IL272367B2 (enExample) |
| MX (1) | MX2020001270A (enExample) |
| MY (1) | MY202018A (enExample) |
| PE (1) | PE20200617A1 (enExample) |
| PH (1) | PH12020500240A1 (enExample) |
| SG (2) | SG10202111869SA (enExample) |
| TW (2) | TWI798242B (enExample) |
| WO (1) | WO2019027935A1 (enExample) |
| ZA (1) | ZA202000608B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2238170T3 (en) | 2008-01-31 | 2017-02-27 | Inserm - Inst Nat De La Santé Et De La Rech Médicale | ANTIBODIES AGAINST HUMAN CD39 AND ITS USE FOR INHIBITING ACTIVITY OF T-REGULATORY CELLS |
| MX2019010848A (es) | 2017-03-16 | 2019-10-30 | Innate Pharma | Composiciones y procedimientos para el tratamiento del cancer. |
| SG10202111869SA (en) | 2017-07-31 | 2021-11-29 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| CN113754768B (zh) * | 2018-03-14 | 2023-01-06 | 表面肿瘤学公司 | 结合cd39的抗体及其用途 |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| JP7368453B2 (ja) | 2018-05-03 | 2023-10-24 | シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド | Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質 |
| JP7500442B2 (ja) | 2018-06-18 | 2024-06-17 | イナート・ファルマ・ソシエテ・アノニム | 癌を処置するための組成物及び方法 |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| EP3927748A1 (en) * | 2019-02-21 | 2021-12-29 | Trishula Therapeutics, Inc. | Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies |
| WO2020172605A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| KR20220061977A (ko) * | 2019-08-12 | 2022-05-13 | 퓨리노미아 바이오테크, 아이엔씨. | Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물 |
| JP7727387B2 (ja) | 2019-08-27 | 2025-08-21 | エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド | 新規の抗ｃｄ３９抗体 |
| US11655303B2 (en) * | 2019-09-16 | 2023-05-23 | Surface Oncology, Inc. | Anti-CD39 antibody compositions and methods |
| CN110407941B (zh) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| US12391756B2 (en) | 2019-11-05 | 2025-08-19 | Jacobio Pharmaceuticals Co., Ltd. | Binding molecule specific for CD39 and use thereof |
| CA3166629A1 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2021203058A2 (en) * | 2020-04-03 | 2021-10-07 | Trishula Therapeutics, Inc. | Combination therapy involving anti-cd39 antibodies and adoptive cell therapy |
| IL299245A (en) | 2020-06-22 | 2023-02-01 | Ngm Biopharmaceuticals Inc | LAIR-1 binding agents and methods of using them |
| WO2021260966A1 (ja) * | 2020-06-25 | 2021-12-30 | 学校法人埼玉医科大学 | アデノシン産生酵素を標的とする組成物 |
| TW202233673A (zh) | 2020-10-23 | 2022-09-01 | 美商雅雪生物治療公司 | 含調節免疫細胞功能之ｃｄ８抗原結合分子之融合物 |
| AU2021389989A1 (en) * | 2020-11-27 | 2023-06-08 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel conjugate molecules targeting cd39 and tgfβeta |
| MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| WO2022245500A1 (en) | 2021-05-19 | 2022-11-24 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| CN118715243A (zh) * | 2022-01-24 | 2024-09-27 | 上海华奥泰生物药业股份有限公司 | Cd39抗原结合蛋白及其应用 |
| KR20240156633A (ko) | 2022-03-03 | 2024-10-30 | 아르커스 바이오사이언시즈 인코포레이티드 | 항-cd39 항체 및 이의 용도 |
| WO2023164872A1 (en) * | 2022-03-03 | 2023-09-07 | Arcus Biosciences, Inc. | Anti-cd39 antibodies and use thereof |
| CN119013304A (zh) * | 2022-03-04 | 2024-11-22 | 翠舒拉治疗股份有限公司 | 在胃癌中使用抗人cd39抗体、抗人pd-1抗体和化疗的组合 |
| WO2023182530A1 (ja) | 2022-03-25 | 2023-09-28 | ブライトパス・バイオ株式会社 | 抗ｃｄ３９抗体 |
| KR20250004779A (ko) | 2022-04-13 | 2025-01-08 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암을 치료하기 위한 병용 요법 |
| WO2024030956A2 (en) * | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
| WO2024115935A1 (en) | 2022-11-29 | 2024-06-06 | Inserm | Methods for the treatment of b-cell lymphoma using cd39 inhibitors |
| WO2024175760A1 (en) * | 2023-02-24 | 2024-08-29 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of endometriosis |
| CN116589584B (zh) * | 2023-05-24 | 2025-02-14 | 深圳市先康达生命科学有限公司 | 靶向人Nectin4蛋白的抗体或其片段和应用 |
| KR102879536B1 (ko) * | 2023-06-09 | 2025-10-31 | 주식회사 브이티 | 시카 추출물이 함침된 마이크로 니들을 유효성분으로 포함하는 화장료 조성물 및 이의 제조방법 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN119798442B (zh) * | 2023-12-27 | 2025-12-16 | 华润生物医药有限公司 | 特异性结合cd39的纳米抗体及其用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4485696A (en) | 1995-01-18 | 1996-08-07 | Boehringer Mannheim Gmbh | Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen |
| WO1996032471A2 (en) | 1995-04-10 | 1996-10-17 | Universite De Sherbrooke | Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology |
| JP2002520040A (ja) | 1998-07-16 | 2002-07-09 | ハイセック，インコーポレーテッド | 新規ｃｄ３９様ポリペプチドに関する方法および材料 |
| US6476211B1 (en) | 1998-07-16 | 2002-11-05 | Hyseq, Inc. | Methods and materials relating to CD39-like polypeptides |
| US6387645B1 (en) | 1998-07-16 | 2002-05-14 | Hyseq, Inc. | Methods and materials relating to novel CD39-like polypeptides |
| US6447771B1 (en) | 1999-03-19 | 2002-09-10 | Hyseq, Inc. | Methods and materials relating to novel CD39-like polypeptides |
| US6350447B1 (en) | 1999-01-29 | 2002-02-26 | Hyseq, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
| US6899875B1 (en) | 1999-01-29 | 2005-05-31 | Nuvelo, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
| US6780977B1 (en) | 1999-01-29 | 2004-08-24 | Nuvelo, Inc. | Methods and compositions relating to CD39-like polypeptides and nucleic acids |
| US6335013B1 (en) | 1999-03-19 | 2002-01-01 | Hyseq, Inc. | Methods and materials relating to CD39-like polypeptides |
| WO2003052121A2 (en) | 2001-12-17 | 2003-06-26 | Beth Israel Deaconess Medical Center | Method of reducing angiogenesis |
| US20050037382A1 (en) | 2003-04-08 | 2005-02-17 | Robson Simon C. | Methods and compositions for treating and preventing autoimmune disorders |
| WO2006111986A1 (en) | 2005-04-19 | 2006-10-26 | Fondazione Santa Lucia I.R.C.C.S. | Method for the detection and the isolation of immunosuppressive regulatory t cells and uses thereof |
| WO2009021754A2 (en) | 2007-08-15 | 2009-02-19 | Bayer Schering Pharma Aktiengesellschaft | Monospecific and multispecific antibodies and method of use |
| EP2211908A2 (en) | 2007-11-30 | 2010-08-04 | Bristol-Myers Squibb Company | Conjugates of anti-rg-1 antibodies |
| DK2238170T3 (en) | 2008-01-31 | 2017-02-27 | Inserm - Inst Nat De La Santé Et De La Rech Médicale | ANTIBODIES AGAINST HUMAN CD39 AND ITS USE FOR INHIBITING ACTIVITY OF T-REGULATORY CELLS |
| DK2356270T3 (da) * | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| DK2654789T3 (en) * | 2010-12-22 | 2018-09-03 | Orega Biotech | ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF |
| US10633451B2 (en) * | 2012-02-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine |
| RU2736495C2 (ru) * | 2014-04-01 | 2020-11-17 | Рубиус Терапьютикс, Инк. | Способ и композиции для иммуномодуляции |
| EP3215538A4 (en) | 2014-11-07 | 2018-07-04 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
| LT3221363T (lt) | 2014-11-21 | 2020-08-10 | Bristol-Myers Squibb Company | Antikūnai prieš cd73 ir jų panaudojimas |
| WO2016191703A2 (en) | 2015-05-27 | 2016-12-01 | The Trustees Of Columbia University In The City Of New York | Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer |
| CN108368176B (zh) | 2015-10-01 | 2022-06-07 | 波滕扎治疗公司 | 抗tigit抗原结合蛋白及其使用方法 |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| CA3005986A1 (en) | 2015-11-23 | 2017-06-01 | Innate Pharma | Cd39 vascular isoform targeting agents |
| EP3912681A1 (en) | 2016-03-14 | 2021-11-24 | Orega Biotech | Anti-cd39 antibodies |
| ES2912453T3 (es) | 2016-05-06 | 2022-05-26 | Inst Nat Sante Rech Med | Composiciones farmacéuticas para el tratamiento de la leucemia mieloide aguda (LMA) quimiorresistente |
| WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
| CN110402249A (zh) | 2016-12-22 | 2019-11-01 | 卡利泰拉生物科技公司 | 外核苷酸酶抑制剂及其使用方法 |
| MX2019010848A (es) | 2017-03-16 | 2019-10-30 | Innate Pharma | Composiciones y procedimientos para el tratamiento del cancer. |
| SG10202111869SA (en) | 2017-07-31 | 2021-11-29 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| EP3692068B1 (en) | 2017-10-06 | 2022-12-07 | Innate Pharma | Restoration of t cell activity via the cd39/cd73 axis |
| CA3075371A1 (en) | 2017-11-15 | 2019-05-23 | Innate Pharma | Potentiating the effect of atp release |
| CN113754768B (zh) | 2018-03-14 | 2023-01-06 | 表面肿瘤学公司 | 结合cd39的抗体及其用途 |
| KR20220061977A (ko) | 2019-08-12 | 2022-05-13 | 퓨리노미아 바이오테크, 아이엔씨. | Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물 |
| JP7727387B2 (ja) | 2019-08-27 | 2025-08-21 | エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド | 新規の抗ｃｄ３９抗体 |
| US11655303B2 (en) | 2019-09-16 | 2023-05-23 | Surface Oncology, Inc. | Anti-CD39 antibody compositions and methods |
| CN110407941B (zh) | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
-
2018
- 2018-07-30 SG SG10202111869SA patent/SG10202111869SA/en unknown
- 2018-07-30 SG SG11202000820PA patent/SG11202000820PA/en unknown
- 2018-07-30 AU AU2018312251A patent/AU2018312251B2/en active Active
- 2018-07-30 WO PCT/US2018/044449 patent/WO2019027935A1/en not_active Ceased
- 2018-07-30 BR BR112020002012A patent/BR112020002012A8/pt unknown
- 2018-07-30 CA CA3071540A patent/CA3071540A1/en active Pending
- 2018-07-30 KR KR1020207005353A patent/KR102718932B1/ko active Active
- 2018-07-30 IL IL272367A patent/IL272367B2/en unknown
- 2018-07-30 EP EP18841649.9A patent/EP3661966A4/en active Pending
- 2018-07-30 IL IL316357A patent/IL316357A/en unknown
- 2018-07-30 CR CR20200101A patent/CR20200101A/es unknown
- 2018-07-30 CN CN201880064027.3A patent/CN111448211B/zh active Active
- 2018-07-30 US US16/049,736 patent/US20190062448A1/en not_active Abandoned
- 2018-07-30 JP JP2020506222A patent/JP7113071B2/ja active Active
- 2018-07-30 CN CN202410622919.8A patent/CN118978594A/zh active Pending
- 2018-07-30 US US16/635,526 patent/US11345757B2/en active Active
- 2018-07-30 MX MX2020001270A patent/MX2020001270A/es unknown
- 2018-07-30 KR KR1020247034153A patent/KR20240153413A/ko active Pending
- 2018-07-30 PE PE2020000166A patent/PE20200617A1/es unknown
- 2018-07-30 MY MYPI2020000520A patent/MY202018A/en unknown
- 2018-07-31 TW TW107126546A patent/TWI798242B/zh active
- 2018-07-31 TW TW112113090A patent/TW202344516A/zh unknown
- 2018-07-31 AR ARP180102152 patent/AR112639A1/es unknown
-
2020
- 2020-01-29 ZA ZA2020/00608A patent/ZA202000608B/en unknown
- 2020-01-31 DO DO2020000021A patent/DOP2020000021A/es unknown
- 2020-01-31 PH PH12020500240A patent/PH12020500240A1/en unknown
- 2020-01-31 CL CL2020000281A patent/CL2020000281A1/es unknown
- 2020-02-25 CO CONC2020/0001983A patent/CO2020001983A2/es unknown
-
2021
- 2021-09-07 US US17/468,366 patent/US20210403593A1/en not_active Abandoned
-
2022
- 2022-04-20 US US17/725,142 patent/US20220340680A1/en not_active Abandoned
- 2022-05-30 US US17/827,989 patent/US20220372163A1/en not_active Abandoned
- 2022-07-25 JP JP2022118008A patent/JP2022145720A/ja not_active Withdrawn
-
2024
- 2024-03-28 JP JP2024053368A patent/JP7690085B2/ja active Active
- 2024-09-24 US US18/895,094 patent/US20250026850A1/en active Pending
-
2025
- 2025-05-28 JP JP2025088950A patent/JP2025116106A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020001983A2 (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anticd39 | |
| CL2023002048A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos | |
| AR109625A1 (es) | Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas | |
| CO2019007846A2 (es) | Proteínas de unión al antígeno anti-neuropilina y sus métodos de uso | |
| MX388350B (es) | Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos. | |
| CO2019009612A2 (es) | Proteinas de unión a antígeno anti-tigit y métodos de uso de las mismas | |
| CO2020005981A2 (es) | Anticuerpos anti-tau y uso de los mismos | |
| CL2018000595A1 (es) | Anticuerpos anti-pd1 y métodos de uso | |
| MX2017007585A (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| CL2017001736A1 (es) | Anticuerpos anti-cd47 y uso de los mismos. | |
| MX2019004690A (es) | Constructos de anticuerpos. | |
| MX2019008359A (es) | Cadena j modificada. | |
| MX2016014247A (es) | Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7). | |
| MX375352B (es) | Reguladores de nrf2. | |
| CR20150247A (es) | Anticuerpos de antihemaglutinina y métodos de uso | |
| CO2019013718A2 (es) | Anticuerpos anti-trkb | |
| CO2019006424A2 (es) | Proteínas de unión a antígenos anti-gitr y métodos de uso de las mismas | |
| MX2017003219A (es) | Derivados de tetrahidroquinolina como inihbidores de bromodominio. | |
| MX2017003949A (es) | Derivados peptidicos novedosos y sus usos. | |
| ECSP18050673A (es) | Formulaciones de giberelina en solución concentrada | |
| JOP20200108A1 (ar) | توليفات شحمية | |
| CL2023000971A1 (es) | Esteroides y conjugados de proteínas de los mismos. | |
| BR112018012313A2 (pt) | composições que compreendem 15-hepe e métodos para uso das mesmas | |
| AR112904A1 (es) | Proteínas de unión a antígenos anti-gitr y métodos para el uso de las mismas |